Eutilex.Co.,Ltd Company Description

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases.

It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.

The company was founded in 2008 and is headquartered in Seoul, South Korea.

Eutilex.Co.,Ltd

Country	South Korea
Founded	2008
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: Suite 408, 4th Floor Seoul, 08591 South Korea
Phone	82 2 2071 3310
Website	eutilex.com

Stock Details

Ticker Symbol	263050
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836